Effect of Influenza Vaccine in Patients With Kidney Transplant
Among infectious diseases, influenza is the most common cause of infection in Japan and worldwide. We aimed to evaluate the effect of influenza vaccination in kidney transplantation (KTx) recipients. We retrospectively evaluated the records of 98 participants who underwent KTx at our institution bet...
Gespeichert in:
| Veröffentlicht in: | Transplantation proceedings 2018-10, Vol.50 (8), p.2443-2446 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2446 |
|---|---|
| container_issue | 8 |
| container_start_page | 2443 |
| container_title | Transplantation proceedings |
| container_volume | 50 |
| creator | Tsujimura, K. Ota, M. Chinen, K. Nagayama, K. Oroku, M. Shiohira, Y. Iseki, K. Ishida, H. Tanabe, K. |
| description | Among infectious diseases, influenza is the most common cause of infection in Japan and worldwide. We aimed to evaluate the effect of influenza vaccination in kidney transplantation (KTx) recipients.
We retrospectively evaluated the records of 98 participants who underwent KTx at our institution between March 2009 and May 2016. All patients received tacrolimus or cyclosporine, mycophenolate mofetil, and methylprednisolone for maintenance immunosuppression after KTx. In accordance with the criteria of our institution, everolimus was administered for the maintenance of immunosuppression after KTx. We compared the rate of influenza infection during the 2016–2017 season (8 months, from October 2016-May 2017) between KTx patients treated with 1 or 2 doses of influenza vaccine (treatment group, n = 71) and KTx patients who did not receive a vaccine (nontreatment group, n = 27).
Among patient characteristics, only the prevalence of diabetes mellitus differed significantly between the groups (treatment group: 9.9%, 7 of 71 patients; nontreatment group: 29.6%, 8 of 21 patients; P = .02). Influenza infection occurred at similar rates in the 2 groups (treatment group, 5.63% 4 of 71 patients; nontreatment group: 3.70%, 1 of 27 patients; P = .70).
Among KTx patients managed in our institution, treatment with 1 or 2 doses of influenza vaccine did not reduce the rate of influenza infection in the 2016–2017 season, suggesting that influenza vaccination may currently be ineffective in KTx patients.
•Influenza is the most common cause of infection in Japan.•We evaluated the effect of the influenza vaccine in kidney transplant recipients.•In the 2016/2017 season, influenza vaccination did not reduce the infection rate. |
| doi_str_mv | 10.1016/j.transproceed.2018.02.186 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2120192839</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0041134518304494</els_id><sourcerecordid>2120192839</sourcerecordid><originalsourceid>FETCH-LOGICAL-c380t-7a415939ee461c90c15e7a7d8fd98bc895e46e86aedf71a6b3673e7f427b48043</originalsourceid><addsrcrecordid>eNqNkE9Lw0AQxRdRbK1-BQmevCTunyS78SBIrVos6KHqcdlsZnFLmtTsRqif3q1twaOnYZg38-b9ELogOCGY5FeLxHeqcauu1QBVQjERCaYJEfkBGhLBWUxzyg7REOOUxISl2QCdOLfAoacpO0YDhhnJGc-G6GZiDGgftSaaNqbuoflW0ZvS2jYQ2SZ6Ud5C4130bv1H9GSrBtbR_Ne-Vo0_RUdG1Q7OdnWEXu8n8_FjPHt-mI5vZ7FmAvuYq5RkBSsA0pzoAmuSAVe8EqYqRKlFkYUBiFxBZThReclyzoCblPIyFThlI3S5vRtCf_bgvFxap6EOP0DbO0lJoFBQwYogvd5Kddc614GRq84uVbeWBMsNP7mQf_nJDT-JqQz8wvL5zqcvl2G2X90DC4K7rQBC2i8LnXQ6ANJQ2S5wlFVr_-PzA49Kh5Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2120192839</pqid></control><display><type>article</type><title>Effect of Influenza Vaccine in Patients With Kidney Transplant</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Tsujimura, K. ; Ota, M. ; Chinen, K. ; Nagayama, K. ; Oroku, M. ; Shiohira, Y. ; Iseki, K. ; Ishida, H. ; Tanabe, K.</creator><creatorcontrib>Tsujimura, K. ; Ota, M. ; Chinen, K. ; Nagayama, K. ; Oroku, M. ; Shiohira, Y. ; Iseki, K. ; Ishida, H. ; Tanabe, K.</creatorcontrib><description>Among infectious diseases, influenza is the most common cause of infection in Japan and worldwide. We aimed to evaluate the effect of influenza vaccination in kidney transplantation (KTx) recipients.
We retrospectively evaluated the records of 98 participants who underwent KTx at our institution between March 2009 and May 2016. All patients received tacrolimus or cyclosporine, mycophenolate mofetil, and methylprednisolone for maintenance immunosuppression after KTx. In accordance with the criteria of our institution, everolimus was administered for the maintenance of immunosuppression after KTx. We compared the rate of influenza infection during the 2016–2017 season (8 months, from October 2016-May 2017) between KTx patients treated with 1 or 2 doses of influenza vaccine (treatment group, n = 71) and KTx patients who did not receive a vaccine (nontreatment group, n = 27).
Among patient characteristics, only the prevalence of diabetes mellitus differed significantly between the groups (treatment group: 9.9%, 7 of 71 patients; nontreatment group: 29.6%, 8 of 21 patients; P = .02). Influenza infection occurred at similar rates in the 2 groups (treatment group, 5.63% 4 of 71 patients; nontreatment group: 3.70%, 1 of 27 patients; P = .70).
Among KTx patients managed in our institution, treatment with 1 or 2 doses of influenza vaccine did not reduce the rate of influenza infection in the 2016–2017 season, suggesting that influenza vaccination may currently be ineffective in KTx patients.
•Influenza is the most common cause of infection in Japan.•We evaluated the effect of the influenza vaccine in kidney transplant recipients.•In the 2016/2017 season, influenza vaccination did not reduce the infection rate.</description><identifier>ISSN: 0041-1345</identifier><identifier>EISSN: 1873-2623</identifier><identifier>DOI: 10.1016/j.transproceed.2018.02.186</identifier><identifier>PMID: 30316375</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Cyclosporine - therapeutic use ; Everolimus - therapeutic use ; Female ; Graft Rejection - prevention & control ; Humans ; Immunosuppressive Agents - therapeutic use ; Influenza Vaccines - immunology ; Influenza Vaccines - therapeutic use ; Influenza, Human - epidemiology ; Influenza, Human - immunology ; Influenza, Human - prevention & control ; Japan ; Kidney Transplantation - adverse effects ; Male ; Methylprednisolone - therapeutic use ; Middle Aged ; Mycophenolic Acid - therapeutic use ; Retrospective Studies ; Tacrolimus - therapeutic use</subject><ispartof>Transplantation proceedings, 2018-10, Vol.50 (8), p.2443-2446</ispartof><rights>2018 Elsevier Inc.</rights><rights>Copyright © 2018 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c380t-7a415939ee461c90c15e7a7d8fd98bc895e46e86aedf71a6b3673e7f427b48043</citedby><cites>FETCH-LOGICAL-c380t-7a415939ee461c90c15e7a7d8fd98bc895e46e86aedf71a6b3673e7f427b48043</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.transproceed.2018.02.186$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30316375$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tsujimura, K.</creatorcontrib><creatorcontrib>Ota, M.</creatorcontrib><creatorcontrib>Chinen, K.</creatorcontrib><creatorcontrib>Nagayama, K.</creatorcontrib><creatorcontrib>Oroku, M.</creatorcontrib><creatorcontrib>Shiohira, Y.</creatorcontrib><creatorcontrib>Iseki, K.</creatorcontrib><creatorcontrib>Ishida, H.</creatorcontrib><creatorcontrib>Tanabe, K.</creatorcontrib><title>Effect of Influenza Vaccine in Patients With Kidney Transplant</title><title>Transplantation proceedings</title><addtitle>Transplant Proc</addtitle><description>Among infectious diseases, influenza is the most common cause of infection in Japan and worldwide. We aimed to evaluate the effect of influenza vaccination in kidney transplantation (KTx) recipients.
We retrospectively evaluated the records of 98 participants who underwent KTx at our institution between March 2009 and May 2016. All patients received tacrolimus or cyclosporine, mycophenolate mofetil, and methylprednisolone for maintenance immunosuppression after KTx. In accordance with the criteria of our institution, everolimus was administered for the maintenance of immunosuppression after KTx. We compared the rate of influenza infection during the 2016–2017 season (8 months, from October 2016-May 2017) between KTx patients treated with 1 or 2 doses of influenza vaccine (treatment group, n = 71) and KTx patients who did not receive a vaccine (nontreatment group, n = 27).
Among patient characteristics, only the prevalence of diabetes mellitus differed significantly between the groups (treatment group: 9.9%, 7 of 71 patients; nontreatment group: 29.6%, 8 of 21 patients; P = .02). Influenza infection occurred at similar rates in the 2 groups (treatment group, 5.63% 4 of 71 patients; nontreatment group: 3.70%, 1 of 27 patients; P = .70).
Among KTx patients managed in our institution, treatment with 1 or 2 doses of influenza vaccine did not reduce the rate of influenza infection in the 2016–2017 season, suggesting that influenza vaccination may currently be ineffective in KTx patients.
•Influenza is the most common cause of infection in Japan.•We evaluated the effect of the influenza vaccine in kidney transplant recipients.•In the 2016/2017 season, influenza vaccination did not reduce the infection rate.</description><subject>Adult</subject><subject>Cyclosporine - therapeutic use</subject><subject>Everolimus - therapeutic use</subject><subject>Female</subject><subject>Graft Rejection - prevention & control</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Influenza Vaccines - immunology</subject><subject>Influenza Vaccines - therapeutic use</subject><subject>Influenza, Human - epidemiology</subject><subject>Influenza, Human - immunology</subject><subject>Influenza, Human - prevention & control</subject><subject>Japan</subject><subject>Kidney Transplantation - adverse effects</subject><subject>Male</subject><subject>Methylprednisolone - therapeutic use</subject><subject>Middle Aged</subject><subject>Mycophenolic Acid - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Tacrolimus - therapeutic use</subject><issn>0041-1345</issn><issn>1873-2623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE9Lw0AQxRdRbK1-BQmevCTunyS78SBIrVos6KHqcdlsZnFLmtTsRqif3q1twaOnYZg38-b9ELogOCGY5FeLxHeqcauu1QBVQjERCaYJEfkBGhLBWUxzyg7REOOUxISl2QCdOLfAoacpO0YDhhnJGc-G6GZiDGgftSaaNqbuoflW0ZvS2jYQ2SZ6Ud5C4130bv1H9GSrBtbR_Ne-Vo0_RUdG1Q7OdnWEXu8n8_FjPHt-mI5vZ7FmAvuYq5RkBSsA0pzoAmuSAVe8EqYqRKlFkYUBiFxBZThReclyzoCblPIyFThlI3S5vRtCf_bgvFxap6EOP0DbO0lJoFBQwYogvd5Kddc614GRq84uVbeWBMsNP7mQf_nJDT-JqQz8wvL5zqcvl2G2X90DC4K7rQBC2i8LnXQ6ANJQ2S5wlFVr_-PzA49Kh5Q</recordid><startdate>201810</startdate><enddate>201810</enddate><creator>Tsujimura, K.</creator><creator>Ota, M.</creator><creator>Chinen, K.</creator><creator>Nagayama, K.</creator><creator>Oroku, M.</creator><creator>Shiohira, Y.</creator><creator>Iseki, K.</creator><creator>Ishida, H.</creator><creator>Tanabe, K.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201810</creationdate><title>Effect of Influenza Vaccine in Patients With Kidney Transplant</title><author>Tsujimura, K. ; Ota, M. ; Chinen, K. ; Nagayama, K. ; Oroku, M. ; Shiohira, Y. ; Iseki, K. ; Ishida, H. ; Tanabe, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c380t-7a415939ee461c90c15e7a7d8fd98bc895e46e86aedf71a6b3673e7f427b48043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Cyclosporine - therapeutic use</topic><topic>Everolimus - therapeutic use</topic><topic>Female</topic><topic>Graft Rejection - prevention & control</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Influenza Vaccines - immunology</topic><topic>Influenza Vaccines - therapeutic use</topic><topic>Influenza, Human - epidemiology</topic><topic>Influenza, Human - immunology</topic><topic>Influenza, Human - prevention & control</topic><topic>Japan</topic><topic>Kidney Transplantation - adverse effects</topic><topic>Male</topic><topic>Methylprednisolone - therapeutic use</topic><topic>Middle Aged</topic><topic>Mycophenolic Acid - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Tacrolimus - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tsujimura, K.</creatorcontrib><creatorcontrib>Ota, M.</creatorcontrib><creatorcontrib>Chinen, K.</creatorcontrib><creatorcontrib>Nagayama, K.</creatorcontrib><creatorcontrib>Oroku, M.</creatorcontrib><creatorcontrib>Shiohira, Y.</creatorcontrib><creatorcontrib>Iseki, K.</creatorcontrib><creatorcontrib>Ishida, H.</creatorcontrib><creatorcontrib>Tanabe, K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tsujimura, K.</au><au>Ota, M.</au><au>Chinen, K.</au><au>Nagayama, K.</au><au>Oroku, M.</au><au>Shiohira, Y.</au><au>Iseki, K.</au><au>Ishida, H.</au><au>Tanabe, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Influenza Vaccine in Patients With Kidney Transplant</atitle><jtitle>Transplantation proceedings</jtitle><addtitle>Transplant Proc</addtitle><date>2018-10</date><risdate>2018</risdate><volume>50</volume><issue>8</issue><spage>2443</spage><epage>2446</epage><pages>2443-2446</pages><issn>0041-1345</issn><eissn>1873-2623</eissn><abstract>Among infectious diseases, influenza is the most common cause of infection in Japan and worldwide. We aimed to evaluate the effect of influenza vaccination in kidney transplantation (KTx) recipients.
We retrospectively evaluated the records of 98 participants who underwent KTx at our institution between March 2009 and May 2016. All patients received tacrolimus or cyclosporine, mycophenolate mofetil, and methylprednisolone for maintenance immunosuppression after KTx. In accordance with the criteria of our institution, everolimus was administered for the maintenance of immunosuppression after KTx. We compared the rate of influenza infection during the 2016–2017 season (8 months, from October 2016-May 2017) between KTx patients treated with 1 or 2 doses of influenza vaccine (treatment group, n = 71) and KTx patients who did not receive a vaccine (nontreatment group, n = 27).
Among patient characteristics, only the prevalence of diabetes mellitus differed significantly between the groups (treatment group: 9.9%, 7 of 71 patients; nontreatment group: 29.6%, 8 of 21 patients; P = .02). Influenza infection occurred at similar rates in the 2 groups (treatment group, 5.63% 4 of 71 patients; nontreatment group: 3.70%, 1 of 27 patients; P = .70).
Among KTx patients managed in our institution, treatment with 1 or 2 doses of influenza vaccine did not reduce the rate of influenza infection in the 2016–2017 season, suggesting that influenza vaccination may currently be ineffective in KTx patients.
•Influenza is the most common cause of infection in Japan.•We evaluated the effect of the influenza vaccine in kidney transplant recipients.•In the 2016/2017 season, influenza vaccination did not reduce the infection rate.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>30316375</pmid><doi>10.1016/j.transproceed.2018.02.186</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1345 |
| ispartof | Transplantation proceedings, 2018-10, Vol.50 (8), p.2443-2446 |
| issn | 0041-1345 1873-2623 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2120192839 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Cyclosporine - therapeutic use Everolimus - therapeutic use Female Graft Rejection - prevention & control Humans Immunosuppressive Agents - therapeutic use Influenza Vaccines - immunology Influenza Vaccines - therapeutic use Influenza, Human - epidemiology Influenza, Human - immunology Influenza, Human - prevention & control Japan Kidney Transplantation - adverse effects Male Methylprednisolone - therapeutic use Middle Aged Mycophenolic Acid - therapeutic use Retrospective Studies Tacrolimus - therapeutic use |
| title | Effect of Influenza Vaccine in Patients With Kidney Transplant |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T05%3A59%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Influenza%20Vaccine%20in%20Patients%20With%20Kidney%20Transplant&rft.jtitle=Transplantation%20proceedings&rft.au=Tsujimura,%20K.&rft.date=2018-10&rft.volume=50&rft.issue=8&rft.spage=2443&rft.epage=2446&rft.pages=2443-2446&rft.issn=0041-1345&rft.eissn=1873-2623&rft_id=info:doi/10.1016/j.transproceed.2018.02.186&rft_dat=%3Cproquest_cross%3E2120192839%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2120192839&rft_id=info:pmid/30316375&rft_els_id=S0041134518304494&rfr_iscdi=true |